135 filings
Page 4 of 7
6-K
FRLN
Freeline Therapeutics Holdings plc
23 Mar 22
Current report (foreign)
4:05pm
424B5
FRLN
Freeline Therapeutics Holdings plc
22 Mar 22
Prospectus supplement for primary offering
4:17pm
SC 13G
FRLN
Freeline Therapeutics Holdings plc
21 Mar 22
Freeline Therapeutics / Tetragon Financial Management ownership change
11:10am
6-K
FRLN
Freeline Therapeutics Holdings plc
15 Mar 22
Current report (foreign)
4:06pm
424B5
FRLN
Freeline Therapeutics Holdings plc
11 Mar 22
Prospectus supplement for primary offering
7:59am
6-K
FRLN
Freeline Therapeutics Holdings plc
9 Mar 22
Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B
7:00am
SC 13G/A
FRLN
Freeline Therapeutics Holdings plc
14 Feb 22
Freeline Therapeutics / EVENTIDE ASSET MANAGEMENT ownership change
11:47am
SC 13G
FRLN
Freeline Therapeutics Holdings plc
11 Feb 22
Freeline Therapeutics / CHI Advisors ownership change
1:00pm
SC 13G/A
FRLN
Freeline Therapeutics Holdings plc
11 Feb 22
Freeline Therapeutics / Syncona Portfolio ownership change
12:20pm
6-K
FRLN
Freeline Therapeutics Holdings plc
8 Feb 22
Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposiumTM
7:00am
SC 13G/A
FRLN
Freeline Therapeutics Holdings plc
4 Feb 22
Freeline Therapeutics / WELLINGTON MANAGEMENT ownership change
9:06am
6-K
FRLN
Freeline Therapeutics Holdings plc
3 Feb 22
Freeline Appoints Henning R. Stennicke, PhD, As Chief Scientific Officer to Lead Research and Discovery
9:01am
6-K
FRLN
Freeline Therapeutics Holdings plc
28 Jan 22
Current report (foreign)
4:00pm
6-K
FRLN
Freeline Therapeutics Holdings plc
6 Jan 22
Freeline Announces FDA Clearance of Investigational New Drug Application
7:00am
6-K
FRLN
Freeline Therapeutics Holdings plc
14 Dec 21
Freeline Announces 2022 Corporate Priorities and Guidance
12:00am
6-K
FRLN
Freeline Therapeutics Holdings plc
13 Dec 21
Freeline Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial
9:02am
6-K
FRLN
Freeline Therapeutics Holdings plc
17 Nov 21
Current report (foreign)
4:03pm
424B5
FRLN
Freeline Therapeutics Holdings plc
17 Nov 21
Prospectus supplement for primary offering
4:02pm
6-K
FRLN
Freeline Therapeutics Holdings plc
9 Nov 21
FRLN Q3-2021 6K-IXBRL
4:02pm
SC 13G/A
Novo Holdings A/S
2 Nov 21
Freeline Therapeutics / Novo Holdings A/S ownership change
4:32pm